Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis

Click to increase image sizeClick to decrease image size

Disclosure statement

L.F.E. has served as a consultant, advisor, or investigator for AbbVie, Amgen, Arcutis, Aslan, Dermavant Sciences, Inc., Eli Lilly, Forté, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, and UCB Pharma. J.I.S. has received honoraria or grants, and/or has served as a consultant, an advisory board member, or speaker for Afyx, AOBiome, Arena, Asana, BiomX, Bluefin Biomedicine, Bodewell, Boehringer Ingelheim, Celgene, Dermavant Sciences Inc., Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, and Sanofi Genzyme. A.A.H. has received research support paid to the medical school from AbbVie, Arcutis, Dermavant Sciences Inc., and Pfizer; honoraria received from GSK, Sanofi Regeneron, and Ortho Dermatologics (as part of a Data Safety Monitoring Board); honoraria received from Dermavant Sciences, Inc., Incyte, LEO Pharma, Pfizer, Arcutis, Sun Pharma, Galderma, Novan, and Verrica. M.B. has been an investigator for Regeneron, Sanofi, and Incyte, and served as a consultant and/or an advisory board member for AbbVie, Amgen, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme.

Additional information

Funding

Editorial assistance was funded by Dermavant Sciences, Inc.